Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03975231 · ClinicalTrials.gov registry record · Phase 1

Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer

A Phase 1 study of Thyroid Gland Anaplastic Carcinoma and BRAF NP_004324.2:p.V600E, sponsored by City of Hope Medical Center.

Recruiting
Registry status
Phase 1
Development phase
6
Enrollment target
3
Study locations

NCT03975231: Recruiting Phase 1 study of Thyroid Gland Anaplastic Carcinoma and BRAF NP_004324.2:p.V600E, sponsored by City of Hope Medical Center.

NCT03975231 is a Phase 1 study of Thyroid Gland Anaplastic Carcinoma and BRAF NP_004324.2:p.V600E that is actively recruiting participants, run by City of Hope Medical Center. The registered enrollment target is 6 participants, below the 37-participant average among 3 other Thyroid Gland Anaplastic Carcinoma trials with a reported enrollment target (84% lower). The trial reports 3 study locations across 3 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03975231, a Phase 1 study of Thyroid Gland Anaplastic Carcinoma and BRAF NP_004324.2:p.V600E, is actively recruiting participants, sponsored by City of Hope Medical Center.

RECRUITING
Registry status
Phase 1
Development phase
6 participants
Enrollment target
3
Study locations

Study Summary

This trial studies how well dabrafenib, trametinib, and intensity modulated radiation therapy (IMRT) work together in treating patients with BRAF mutated anaplastic thyroid cancer. Dabrafenib and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Radiation therapy uses high energy beams to kill tumor cells and shrink tumors. Giving dabrafenib, trametinib, and IMRT together may kill more tumor cells.

Conditions Studied

Thyroid Gland Anaplastic Carcinoma BRAF NP_004324.2:p.V600E BRAF V600K Mutation Present

Interventions

  • RADIATION Intensity-Modulated Radiation Therapy
  • DRUG Trametinib
  • DRUG Dabrafenib

Study Locations (3)

California

  • City of Hope Medical Center - Duarte

Ohio

  • Ohio State University Comprehensive Cancer Center - Columbus

Texas

  • Univ of Texas-M.D. Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 6 participants
Start Date 2020-09-14
Est. Completion 2026-02-28
Phase Phase 1
City of Hope Medical Center

582 total trials

What NCT03975231 shows while recruiting

NCT03975231 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 37-participant average among 3 other Thyroid Gland Anaplastic Carcinoma trials with a reported enrollment target (84% lower).

The record links to 3 conditions, with Thyroid Gland Anaplastic Carcinoma appearing as the primary indexed condition, and to 3 interventions - of which Intensity-Modulated Radiation Therapy is the first listed.

NCT03975231 reports a single indexed study location in California, Ohio, Texas.

Frequently Asked Questions

What is clinical trial NCT03975231 about?

NCT03975231 is a clinical study titled "Dabrafenib, Trametinib, and IMRT in Treating Patients With BRAF Mutated Anaplastic Thyroid Cancer". This trial studies how well dabrafenib, trametinib, and intensity modulated radiation therapy (IMRT) work together in treating patients with BRAF mutated anaplastic thyroid cancer. Dabrafenib and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Ra...

What is the current status of trial NCT03975231?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2020-09-14. Estimated completion is 2026-02-28.

What conditions does trial NCT03975231 study?

This clinical trial studies the following conditions: Thyroid Gland Anaplastic Carcinoma, BRAF NP_004324.2:p.V600E, BRAF V600K Mutation Present.

What interventions are being tested in trial NCT03975231?

The interventions under investigation include: Intensity-Modulated Radiation Therapy (RADIATION), Trametinib (DRUG), Dabrafenib (DRUG).

Who is sponsoring clinical trial NCT03975231?

This trial is sponsored by City of Hope Medical Center, which has 582 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03975231 being conducted?

This trial has 3 study locations across California, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Thyroid Gland Anaplastic Carcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT03975231

Source: ClinicalTrials.gov NCT03975231, the US trial registry maintained by the National Library of Medicine. NCT03975231 (small enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.